Neurostim tech developer Helius Medical prices $18M offering

2022-08-05

Newtown, Pennsylvania-based Helius, which develops the PoNS (portable neuromodulation stimulator), is offering 24 million shares of Class A common stock and warrants to purchase up to 36 million shares of Class A common stock at a purchase price of 75¢ per share. The public warrants in the offering will have an exercise price of 75¢ per share and are exercisable upon issuance with expiration after five years following the date of issuance. Helius expects the offering to close on or about Aug. 9, subject to customary closing conditions. Roth Capital Partners, LLC is acting as lead placement agent, and Maxim Group LLC is acting as co-placement agent of the offering. The company said in a news release that the $18 million in gross proceeds is earmarked for funding operations, working capital and other general corporate purposes.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构